{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:26:17Z","timestamp":1783081577921,"version":"3.54.6"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00105-026-05710-5","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:25:15Z","timestamp":1780392315000},"page":"441-447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronische Prurigo: Pathophysiologie, Diagnostik und Therapie im \u00dcberblick","Chronic prurigo: overview of pathophysiology, diagnosis, and treatment"],"prefix":"10.1007","volume":"77","author":[{"given":"Felix","family":"Witte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Zeidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"5710_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jid.2022.08.042","volume":"143","author":"K Agelopoulos","year":"2023","unstructured":"Agelopoulos\u00a0K, Renkhold\u00a0L, Wiegmann\u00a0H et\u00a0al (2023) Transcriptomic, Epigenomic, and Neuroanatomic Signatures Differ in Chronic Prurigo, Atopic Dermatitis, and Brachioradial Pruritus. J\u00a0Invest Dermatol 143:264\u2013272.e263","journal-title":"J Invest Dermatol"},{"key":"5710_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jaci.2023.04.019","volume":"152","author":"N Alkon","year":"2023","unstructured":"Alkon\u00a0N, Assen\u00a0FP, Arnoldner\u00a0T et\u00a0al (2023) Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis. J\u00a0Allergy Clin Immunol 152:420\u2013435","journal-title":"J Allergy Clin Immunol"},{"key":"5710_CR3","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1111\/jdv.17485","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin\u00a0M, Garbe\u00a0C, Hagenstr\u00f6m\u00a0K et\u00a0al (2021) Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: A population-based claims data analysis. J\u00a0Eur Acad Dermatol Venereol 35:2270\u20132276","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5710_CR4","first-page":"822","volume":"21","author":"M Augustin","year":"2023","unstructured":"Augustin\u00a0M, Zeidler\u00a0C, Von Kiedrowski\u00a0R et\u00a0al (2023) Indikation zur Systemtherapie bei chronischer Prurigo: Kommentierte Checkliste f\u00fcr die Praxis. J\u00a0Dtsch Dermatol Ges 21:822\u2013824","journal-title":"J Dtsch Dermatol Ges"},{"key":"5710_CR5","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1093\/ced\/llaf302","volume":"50","author":"G Avallone","year":"2025","unstructured":"Avallone\u00a0G, Bombelli\u00a0A, Valtellini\u00a0L et\u00a0al (2025) Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis. Clin Exp Dermatol 50:2211\u20132220","journal-title":"Clin Exp Dermatol"},{"key":"5710_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2340\/00015555-2232","volume":"96","author":"S Bobko","year":"2016","unstructured":"Bobko\u00a0S, Zeidler\u00a0C, Osada\u00a0N et\u00a0al (2016) Intraepidermal Nerve Fibre Density is Decreased in Lesional and Inter-lesional Prurigo Nodularis and Reconstitutes on Healing of Lesions. Acta Derm Venereol 96:404\u2013406","journal-title":"Acta Derm Venereol"},{"key":"5710_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/jdv.15145","volume":"33","author":"E Brenaut","year":"2019","unstructured":"Brenaut\u00a0E, Halvorsen\u00a0JA, Dalgard\u00a0FJ et\u00a0al (2019) The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries. J\u00a0Eur Acad Dermatol Venereol 33:157\u2013162","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5710_CR8","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.jid.2023.05.011","volume":"143","author":"A Calugareanu","year":"2023","unstructured":"Calugareanu\u00a0A, Specque\u00a0F, Demouche\u00a0S et\u00a0al (2023) Transcriptomic Landscape of Prurigo Nodularis Lesional Skin CD3+ T Cells Using Single-Cell RNA Sequencing. J\u00a0Invest Dermatol 143:2525\u20132529.e2525","journal-title":"J Invest Dermatol"},{"key":"5710_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/bjd\/ljad121","volume":"189","author":"S Choragudi","year":"2023","unstructured":"Choragudi\u00a0S, Yosipovitch\u00a0G (2023) Prurigo nodularis is highly linked with neural sensitization disorders of pain among hospitalized adults in the United States - National Inpatient Sample 2016-2019. Br J Dermatol 189:240\u2013242","journal-title":"Br J Dermatol"},{"key":"5710_CR10","doi-asserted-by":"crossref","unstructured":"Czerwi\u0144ska J, Owczarczyk-Saczonek A (2025) Matrix Metalloproteinases in Inflammatory Dermatoses. Int J Mol Sci\u00a026","DOI":"10.3390\/ijms262110319"},{"key":"5710_CR11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky\u00a0W, King\u00a0BA (2017) JAK inhibitors in dermatology: The promise of a new drug class. J\u00a0Am Acad Dermatol 76:736\u2013744","journal-title":"J Am Acad Dermatol"},{"key":"5710_CR12","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1111\/all.14791","volume":"76","author":"A Datsi","year":"2021","unstructured":"Datsi\u00a0A, Steinhoff\u00a0M, Ahmad\u00a0F et\u00a0al (2021) Interleukin-31: The \u201citchy\u201d cytokine in inflammation and therapy. Allergy 76:2982\u20132997","journal-title":"Allergy"},{"key":"5710_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1022889","volume":"9","author":"J Deng","year":"2022","unstructured":"Deng\u00a0J, Parthasarathy\u00a0V, Marani\u00a0M et\u00a0al (2022) Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis. Front Med (Lausanne) 9:1022889","journal-title":"Front Med (Lausanne)"},{"key":"5710_CR14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/pde.14464","volume":"38","author":"T Fachler","year":"2021","unstructured":"Fachler\u00a0T, Faitataziadou\u00a0M, Molho-Pessach\u00a0V (2021) Dupilumab for pediatric prurigo nodularis: A\u00a0case report. Pediatr Dermatol 38:334\u2013335","journal-title":"Pediatr Dermatol"},{"key":"5710_CR15","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/1346-8138.16803","volume":"50","author":"HY Fang","year":"2023","unstructured":"Fang\u00a0HY, Lian\u00a0CH (2023) The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study. J\u00a0Dermatol 50:1084\u20131087","journal-title":"J Dermatol"},{"key":"5710_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1684\/ejd.2020.3947","volume":"31","author":"M Giovannini","year":"2021","unstructured":"Giovannini\u00a0M, Mori\u00a0F, Oranges\u00a0T et\u00a0al (2021) Dupilumab treatment of prurigo nodularis in an adolescent. Eur J Dermatol 31:104\u2013106","journal-title":"Eur J Dermatol"},{"key":"5710_CR17","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3571","volume":"100","author":"S Gr\u00fcndel","year":"2020","unstructured":"Gr\u00fcndel\u00a0S, Pereira\u00a0MP, Storck\u00a0M et\u00a0al (2020) Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment. Acta Derm Venereol 100:adv00269","journal-title":"Acta Derm Venereol"},{"key":"5710_CR18","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/exd.14279","volume":"30","author":"T Hashimoto","year":"2021","unstructured":"Hashimoto\u00a0T, Nattkemper\u00a0LA, Kim\u00a0HS et\u00a0al (2021) Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol 30:804\u2013810","journal-title":"Exp Dermatol"},{"key":"5710_CR19","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1111\/jdv.18942","volume":"37","author":"T Hashimoto","year":"2023","unstructured":"Hashimoto\u00a0T, Okuno\u00a0S, Okuzawa\u00a0M, Satoh\u00a0T (2023) Increased sensitivity to touch-evoked itch (punctate hyperknesis) in prurigo nodularis and type 2 inflammation: A cross-sectional pilot study. J\u00a0Eur Acad Dermatol Venereol 37:e789\u2013e791","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5710_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","volume":"140","author":"AH Huang","year":"2020","unstructured":"Huang\u00a0AH, Canner\u00a0JK, Khanna\u00a0R et\u00a0al (2020) Real-World Prevalence of Prurigo Nodularis and Burden of Associated Diseases. J\u00a0Invest Dermatol 140:480\u2013483.e484","journal-title":"J Invest Dermatol"},{"key":"5710_CR21","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","volume":"83","author":"AH Huang","year":"2020","unstructured":"Huang\u00a0AH, Williams\u00a0KA, Kwatra\u00a0SG (2020) Prurigo nodularis: Epidemiology and clinical features. J\u00a0Am Acad Dermatol 83:1559\u20131565","journal-title":"J Am Acad Dermatol"},{"key":"5710_CR22","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1080\/09546634.2020.1853024","volume":"33","author":"H Husein-Elahmed","year":"2022","unstructured":"Husein-Elahmed\u00a0H, Steinhoff\u00a0M (2022) Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. J\u00a0Dermatolog Treat 33:1547\u20131553","journal-title":"J Dermatolog Treat"},{"key":"5710_CR23","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1111\/jdv.13827","volume":"31","author":"KM J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen\u00a0KM, Egeberg\u00a0A, Gislason\u00a0GH et\u00a0al (2017) Anxiety, depression and suicide in patients with prurigo nodularis. J\u00a0Eur Acad Dermatol Venereol 31:e106\u2013e107","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5710_CR24","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1097\/01.MLR.0000093487.78664.3C","volume":"41","author":"K Kroenke","year":"2003","unstructured":"Kroenke\u00a0K, Spitzer\u00a0RL, Williams\u00a0JB (2003) The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 41:1284\u20131292","journal-title":"Med Care"},{"key":"5710_CR25","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamadermatol.2024.1464","volume":"160","author":"SG Kwatra","year":"2024","unstructured":"Kwatra\u00a0SG, Bordeaux\u00a0ZA, Parthasarathy\u00a0V et\u00a0al (2024) Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin: A\u00a0Nonrandomized Controlled Trial. JAMA Dermatol 160:717\u2013724","journal-title":"JAMA Dermatol"},{"key":"5710_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jid.2024.06.1276","volume":"145","author":"SG Kwatra","year":"2025","unstructured":"Kwatra\u00a0SG, St\u00e4nder\u00a0S, Yosipovitch\u00a0G et\u00a0al (2025) Pathophysiology of Prurigo Nodularis: Neuroimmune Dysregulation and the Role of Type 2 Inflammation. J\u00a0Invest Dermatol 145:249\u2013256","journal-title":"J Invest Dermatol"},{"key":"5710_CR27","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","volume":"389","author":"SG Kwatra","year":"2023","unstructured":"Kwatra\u00a0SG, Yosipovitch\u00a0G, Legat\u00a0FJ et\u00a0al (2023) Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. N\u00a0Engl J Med 389:1579\u20131589","journal-title":"N Engl J Med"},{"key":"5710_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/ITT.S316602","volume":"11","author":"A Labib","year":"2022","unstructured":"Labib\u00a0A, Ju\u00a0T, Vander Does\u00a0A, Yosipovitch\u00a0G (2022) Immunotargets and Therapy for Prurigo Nodularis. Immunotargets Ther 11:11\u201321","journal-title":"Immunotargets Ther"},{"key":"5710_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.clindermatol.2025.03.007","volume":"43","author":"HJ Lee","year":"2025","unstructured":"Lee\u00a0HJ, Kim\u00a0HS (2025) Prurigo nodularis and the microbiome. Clin Dermatol 43:649\u2013655","journal-title":"Clin Dermatol"},{"key":"5710_CR30","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.jaad.2025.08.022","volume":"93","author":"M Metz","year":"2025","unstructured":"Metz\u00a0M, St\u00e4nder\u00a0S, Moiin\u00a0A et\u00a0al (2025) Safety and efficacy of barzolvolimab, an anti-KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single dose study. J\u00a0Am Acad Dermatol 93:1596\u20131599","journal-title":"J Am Acad Dermatol"},{"key":"5710_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen\u00a0LK, Mack\u00a0MR, Feng\u00a0J et\u00a0al (2017) Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch. Cell 171:217\u2013228.e213","journal-title":"Cell"},{"key":"5710_CR32","unstructured":"Pereira MP, Butze M, Vera Ayala C et\u00a0al. (2025) The Role of Mast Cells in the Pathophysiology of Chronic Prurigo. J\u00a0Invest Dermatol"},{"key":"5710_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00105-018-4145-2","volume":"69","author":"MP Pereira","year":"2018","unstructured":"Pereira\u00a0MP, Nau\u00a0T, Zeidler\u00a0C, St\u00e4nder\u00a0S (2018) Chronic prurigo. Hautarzt 69:321\u2013330","journal-title":"Hautarzt"},{"key":"5710_CR34","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/exd.13343","volume":"26","author":"MP Pereira","year":"2017","unstructured":"Pereira\u00a0MP, Pogatzki-Zahn\u00a0E, Snels\u00a0C et\u00a0al (2017) There is no functional small-fibre neuropathy in prurigo nodularis despite neuroanatomical alterations. Exp Dermatol 26:969\u2013971","journal-title":"Exp Dermatol"},{"key":"5710_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.alit.2016.08.009","volume":"66","author":"MP Pereira","year":"2017","unstructured":"Pereira\u00a0MP, St\u00e4nder\u00a0S (2017) Assessment of severity and burden of pruritus. Allergol Int 66:3\u20137","journal-title":"Allergol Int"},{"key":"5710_CR36","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/jdv.14570","volume":"32","author":"MP Pereira","year":"2018","unstructured":"Pereira\u00a0MP, Steinke\u00a0S, Zeidler\u00a0C et\u00a0al (2018) European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J\u00a0Eur Acad Dermatol Venereol 32:1059\u20131065","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5710_CR37","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3726","volume":"101","author":"MP Pereira","year":"2021","unstructured":"Pereira\u00a0MP, Zeidler\u00a0C, Wallengren\u00a0J et\u00a0al (2021) Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction. Acta Derm Venereol 101:adv00403","journal-title":"Acta Derm Venereol"},{"key":"5710_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jid.2019.05.029","volume":"140","author":"EM Pogatzki-Zahn","year":"2020","unstructured":"Pogatzki-Zahn\u00a0EM, Pereira\u00a0MP, Cremer\u00a0A et\u00a0al (2020) Peripheral Sensitization and Loss of Descending Inhibition Is a Hallmark of Chronic Pruritus. J\u00a0Invest Dermatol 140:203\u2013211.e204","journal-title":"J Invest Dermatol"},{"key":"5710_CR39","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin\u00a0D, Passeron\u00a0T, Pandya\u00a0AG et\u00a0al (2022) Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N\u00a0Engl J Med 387:1445\u20131455","journal-title":"N Engl J Med"},{"key":"5710_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1365-2133.2011.10306.x","volume":"165","author":"B Schuhknecht","year":"2011","unstructured":"Schuhknecht\u00a0B, Marziniak\u00a0M, Wissel\u00a0A et\u00a0al (2011) Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a\u00a0potential sign of subclinical cutaneous neuropathy. Br J Dermatol 165:85\u201391","journal-title":"Br J Dermatol"},{"key":"5710_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/exd.14678","volume":"32","author":"Y Shao","year":"2023","unstructured":"Shao\u00a0Y, Zhu\u00a0Y, Xiao\u00a0Z et\u00a0al (2023) RNA sequencing reveals the transcriptome profile of the atopic prurigo nodularis with severe itching. Exp Dermatol 32:30\u201340","journal-title":"Exp Dermatol"},{"key":"5710_CR42","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3655","volume":"100","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder\u00a0S, Ketz\u00a0M, Kossack\u00a0N et\u00a0al (2020) Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis. Acta Derm Venereol 100:adv00309","journal-title":"Acta Derm Venereol"},{"key":"5710_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/itx.0000000000000042","volume":"5","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder\u00a0S, Pereira\u00a0MP, Berger\u00a0T et\u00a0al (2020) IFSI-guideline on chronic prurigo including prurigo nodularis. Itch 5:e42","journal-title":"Itch"},{"key":"5710_CR44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","volume":"161","author":"S St\u00e4nder","year":"2025","unstructured":"St\u00e4nder\u00a0S, Yosipovitch\u00a0G, Legat\u00a0FJ et\u00a0al (2025) Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial. JAMA Dermatol 161:147\u2013156","journal-title":"JAMA Dermatol"},{"key":"5710_CR45","doi-asserted-by":"crossref","unstructured":"St\u00e4nder S, Yosipovitch G, Sofen H et\u00a0al. (2025) Vixarelimab in Patients With Prurigo Nodularis: A\u00a0Randomized Clinical Trial. JAMA Dermatol","DOI":"10.1001\/jamadermatol.2025.4950"},{"key":"5710_CR46","unstructured":"St\u00e4nder S, Zeidler C, Augustin M et\u00a0al. (2026) S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus. im Druck."},{"key":"5710_CR47","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/jdv.17111","volume":"35","author":"M Storck","year":"2021","unstructured":"Storck\u00a0M, Sandmann\u00a0S, Bruland\u00a0P et\u00a0al (2021) Pruritus Intensity Scales across Europe: a prospective validation study. J\u00a0Eur Acad Dermatol Venereol 35:1176\u20131185","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5710_CR48","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/bjd.13492","volume":"172","author":"A Stumpf","year":"2015","unstructured":"Stumpf\u00a0A, St\u00e4nder\u00a0S, Warlich\u00a0B et\u00a0al (2015) Relations between the characteristics and psychological comorbidities of chronic pruritus differ between men and women: women are more anxious than men. Br J Dermatol 172:1323\u20131328","journal-title":"Br J Dermatol"},{"key":"5710_CR49","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.jid.2022.02.010","volume":"142","author":"N Sutaria","year":"2022","unstructured":"Sutaria\u00a0N, Alphonse\u00a0MP, Roh\u00a0YS et\u00a0al (2022) Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene Dysregulation in Prurigo Nodularis Compared with Psoriasis and Atopic Dermatitis. J\u00a0Invest Dermatol 142:2537\u20132540","journal-title":"J Invest Dermatol"},{"key":"5710_CR50","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jaci.2021.10.004","volume":"149","author":"LC Tsoi","year":"2022","unstructured":"Tsoi\u00a0LC, Hacini-Rachinel\u00a0F, Fogel\u00a0P et\u00a0al (2022) Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J\u00a0Allergy Clin Immunol 149:1329\u20131339","journal-title":"J Allergy Clin Immunol"},{"key":"5710_CR51","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1600-0560.2009.01484.x","volume":"37","author":"N Weigelt","year":"2010","unstructured":"Weigelt\u00a0N, Metze\u00a0D, St\u00e4nder\u00a0S (2010) Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J\u00a0Cutan Pathol 37:578\u2013586","journal-title":"J Cutan Pathol"},{"key":"5710_CR52","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.44220","volume":"105","author":"E Weisshaar","year":"2025","unstructured":"Weisshaar\u00a0E, M\u00fcller\u00a0S, Szepietowski\u00a0JC et\u00a0al (2025) European S2k Guideline on Chronic Pruritus. Acta Derm Venereol 105:adv44220","journal-title":"Acta Derm Venereol"},{"key":"5710_CR53","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","volume":"83","author":"KA Williams","year":"2020","unstructured":"Williams\u00a0KA, Huang\u00a0AH, Belzberg\u00a0M, Kwatra\u00a0SG (2020) Prurigo nodularis: Pathogenesis and management. J\u00a0Am Acad Dermatol 83:1567\u20131575","journal-title":"J Am Acad Dermatol"},{"key":"5710_CR54","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00105-024-05375-y","volume":"75","author":"F Witte","year":"2024","unstructured":"Witte\u00a0F, St\u00e4nder\u00a0S, Zeidler\u00a0C (2024) Treatment of chronic prurigo: update and perspectives. Dermatologie (Heidelb) 75:623\u2013628","journal-title":"Dermatologie (Heidelb)"},{"key":"5710_CR55","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch\u00a0G, Mollanazar\u00a0N, St\u00e4nder\u00a0S et\u00a0al (2023) Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med 29:1180\u20131190","journal-title":"Nat Med"},{"key":"5710_CR56","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/jdv.16929","volume":"35","author":"C Zeidler","year":"2021","unstructured":"Zeidler\u00a0C, Pereira\u00a0MP, Dugas\u00a0M et\u00a0al (2021) The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non-lesional skin: A comparative, retrospective, explorative statistical analysis of 4,484 patients in a real-world cohort. J\u00a0Eur Acad Dermatol Venereol 35:738\u2013743","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05710-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05710-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05710-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:03:50Z","timestamp":1783080230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05710-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5710"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05710-5","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Witte ist oder war Berater f\u00fcr Galderma. C.\u00a0Zeidler ist oder war Beraterin, Referentin oder Pr\u00fcferin f\u00fcr AbbVie, Almirall, Beiersdorf, Boehringer Ingelheim, DERFO, Dermasence, Galderma, Janssen, Leo, Lilly, Novartis, Pfizer, Regeneron, Sanofi, UCB, Unna Akademie. S.\u00a0St\u00e4nder ist oder war Beraterin, Referentin oder Pr\u00fcferin f\u00fcr AbbVie Deutschland GmbH & Co., Almirall Hermal GmbH, Almirall S.A., Amgen Inc., Amgen Europe GmbH, Attovia Therapeutics Inc., Beiersdorf AG, Bellus Health Cough Inc., Bristol-Meyers Squibb Company, Celldex Therapeutics Inc., Clexio Biosiences Ltd., CRM GmbH, Focus-Insight Healthtech Group Co. Ltd., FomF GmbH, Galderma S.A., Galderma Laboratorium GmbH, Galderma R & D, LLC., Gr\u00fcnenthal GmbH, Innocare Pharma, Klirna Biotech Inc., Lilly Deutschland GmbH, L\u2019Or\u00e9al, Novartis Pharma GmbH, Omnicuris Healthcare Private Ltd., Pfizer Pharma GmbH, Pfizer Inc., P.\u00a0G. Unna Academy, Regeneron Pharmaceuticals Inc., Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis R & D, Sanofi Genzyme Corporation, Sanofi-Aventis (Schweiz) AG, Sanofi B.V., Sanofi Genzyme Europe B.V., Sanofi Hong Kong Ltd., Sanofi OY, Streamed-Up! GmbH, TouchIME, UCB Pharma GmbH, Trevi Therapeutics Inc., Vifor Pharma Deutschland GmbH, WebMD Global LLC, Zai Laboratory.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}